Advertisement

Tumor Biology

, Volume 35, Issue 12, pp 12255–12263 | Cite as

Prognostic significance of Bcl-2 expression in non-basal triple-negative breast cancer patients treated with anthracycline-based chemotherapy

  • Jung Eun Choi
  • Su Hwan Kang
  • Soo Jung Lee
  • Young Kyung Bae
Research Article

Abstract

B cell lymphoma/leukemia-2 (Bcl-2) expression has generally been associated with estrogen receptor positivity and favorable prognosis in breast cancer. We examined immunohistochemical expression of Bcl-2 in 492 triple-negative breast cancers (TNBCs) using tissue microarrays and investigated its correlation with clinicopathologic features and clinical outcome. A total of 47 (9.5 %) TNBCs showed Bcl-2 expression. Bcl-2 expression was not associated with any of the clinicopathologic parameters and did not affect patient survival in TNBCs (Bcl-2-positive vs Bcl-2-negative TNBCs; overall survival (OS), P = 0.258; disease-free survival (DFS), P = 0.436). When TNBCs were divided into basal (cytokeratin 5/6 (CK5/6)+ and/or epidermal growth factor receptor (EGFR)+) and non-basal (CK5/6− and EGFR−) subgroups, Bcl-2 expression showed a significant association with worse OS (P = 0.002) and DFS (P = 0.002) in the non-basal subgroup. Among patients treated with an anthracycline, Bcl-2 expression also showed an association with decreased survival (OS, P = 0.004; DFS, P = 0.003) in the non-basal subgroup. In multivariate analyses, Bcl-2 expression was an independent poor prognostic factor for OS (P = 0.003) and DFS (P = 0.002) in this subgroup of TNBCs. Our results suggest that positive expression of Bcl-2 predicts no benefit from adjuvant anthracycline-based chemotherapy in non-basal TNBC patients. In conclusion, Bcl-2 status showed both prognostic and predictive values in non-basal TNBCs; therefore, assessment of Bcl-2 status and basal phenotype can provide information on prognostic and therapeutic classifications of TNBCs.

Keywords

Bcl-2 Immunohistochemistry Triple-negative breast cancer Non-basal triple-negative breast cancer Anthracycline Prognosis 

Notes

Conflicts of interest

None

References

  1. 1.
    Tsujimoto Y, Croce CM. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci U S A. 1986;83:5214–8.PubMedCentralPubMedCrossRefGoogle Scholar
  2. 2.
    Frenzel A, Grespi F, Chmelewskij W, Villunger A. Bcl2 family proteins in carcinogenesis and the treatment of cancer. Apoptosis. 2009;14:584–96.PubMedCentralPubMedCrossRefGoogle Scholar
  3. 3.
    Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol. 1994;124:1–6.PubMedCrossRefGoogle Scholar
  4. 4.
    Callagy GM, Webber MJ, Pharoah PD, Caldas C. Meta-analysis confirms BCL2 is an independent prognostic marker in breast cancer. BMC Cancer. 2008;8:153. 2407-8-153.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Tawfik K, Kimler BF, Davis MK, Fan F, Tawfik O. Prognostic significance of Bcl-2 in invasive mammary carcinomas: a comparative clinicopathologic study between “triple-negative” and non-“triple-negative” tumors. Hum Pathol. 2012;43:23–30.PubMedCrossRefGoogle Scholar
  6. 6.
    Subhawong AP, Nassar H, Halushka MK, Illei PB, Vang R, Argani P. Heterogeneity of Bcl-2 expression in metastatic breast carcinoma. Mod Pathol. 2010;23:1089–96.PubMedCrossRefGoogle Scholar
  7. 7.
    Trere D, Montanaro L, Ceccarelli C, Barbieri S, Cavrini G, Santini D, et al. Prognostic relevance of a novel semiquantitative classification of Bcl2 immunohistochemical expression in human infiltrating ductal carcinomas of the breast. Ann Oncol. 2007;18:1004–14.PubMedCrossRefGoogle Scholar
  8. 8.
    Callagy GM, Pharoah PD, Pinder SE, Hsu FD, Nielsen TO, Ragaz J, et al. Bcl-2 is a prognostic marker in breast cancer independently of the Nottingham Prognostic Index. Clin Cancer Res. 2006;12:2468–75.PubMedCrossRefGoogle Scholar
  9. 9.
    Lipponen P, Pietilainen T, Kosma VM, Aaltomaa S, Eskelinen M, Syrjanen K. Apoptosis suppressing protein bcl-2 is expressed in well-differentiated breast carcinomas with favourable prognosis. J Pathol. 1995;177:49–55.PubMedCrossRefGoogle Scholar
  10. 10.
    Dawson SJ, Makretsov N, Blows FM, Driver KE, Provenzano E, Le Quesne J, et al. BCL2 in breast cancer: a favourable prognostic marker across molecular subtypes and independent of adjuvant therapy received. Br J Cancer. 2010;103:668–75.PubMedCentralPubMedCrossRefGoogle Scholar
  11. 11.
    Hwang KT, Woo JW, Shin HC, Kim HS, Ahn SK, Moon HG, et al. Prognostic influence of BCL2 expression in breast cancer. Int J Cancer. 2012;131:E1109–19.PubMedCrossRefGoogle Scholar
  12. 12.
    Abdel-Fatah TM, Perry C, Dickinson P, Ball G, Moseley P, Madhusudan S, et al. Bcl2 is an independent prognostic marker of triple negative breast cancer (TNBC) and predicts response to anthracycline combination (ATC) chemotherapy (CT) in adjuvant and neoadjuvant settings. Ann Oncol. 2013;24:2801–7.PubMedCrossRefGoogle Scholar
  13. 13.
    Rhee J, Han SW, Oh DY, Kim JH, Im SA, Han W, et al. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. BMC Cancer. 2008;8:307. 2407-8-307.PubMedCentralPubMedCrossRefGoogle Scholar
  14. 14.
    Kwon SY, Bae YK, Gu MJ, Choi JE, Kang SH, Lee SJ, et al. Neuroendocrine differentiation correlates with hormone receptor expression and decreased survival in patients with invasive breast carcinoma. Histopathology. 2014;64:647–59.PubMedCrossRefGoogle Scholar
  15. 15.
    Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol. 2010;28:2784–95.PubMedCentralPubMedCrossRefGoogle Scholar
  16. 16.
    Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol. 2013;31:3997–4013.PubMedCrossRefGoogle Scholar
  17. 17.
    Park HS, Jang MH, Kim EJ, Kim HJ, Lee HJ, Kim YJ, et al. High EGFR gene copy number predicts poor outcome in triple-negative breast cancer. Mod Pathol. 2014. doi: 10.1038/modpathol.2013.251.Google Scholar
  18. 18.
    Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004;351:2817–26.PubMedCrossRefGoogle Scholar
  19. 19.
    Ali HR, Dawson SJ, Blows FM, Provenzano E, Leung S, Nielsen T, et al. A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer. J Pathol. 2012;226:97–107.PubMedCrossRefGoogle Scholar
  20. 20.
    Lee JY, Kim HA, Kim EK, Yang HM, Kim KI, Lee JI, et al. Different prognostic significance of bcl-2 based on cancer molecular subtype. J Breast Cancer. 2011;14:S10–6.CrossRefGoogle Scholar
  21. 21.
    Choi YL, Oh E, Park S, Kim Y, Park YH, Song K, et al. Triple-negative, basal-like, and quintuple-negative breast cancers: better prediction model for survival. BMC Cancer. 2010;10:507. 2407-10-507.PubMedCentralPubMedCrossRefGoogle Scholar
  22. 22.
    Lee KH, Im SA, Oh DY, Lee SH, Chie EK, Han W, et al. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy. BMC Cancer. 2007;7:63.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Bouchalova K, Svoboda M, Kharaishvili G, Radova L, Bouchal J, Trojanec R, et al. BCL2 protein in prediction of relapse in triple-negative breast cancer (TNBC) treated with adjuvant anthracycline-based chemotherapy. J Clin Oncol. 2012;30:Suppl; abstr 1087.Google Scholar
  24. 24.
    Emi M, Kim R, Tanabe K, Uchida Y, Toge T. Targeted therapy against Bcl-2-related proteins in breast cancer cells. Breast Cancer Res. 2005;7:R940–52.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Buchholz TA, Garg AK, Chakravarti N, Aggarwal BB, Esteva FJ, Kuerer HM, et al. The nuclear transcription factor kappaB/bcl-2 pathway correlates with pathologic complete response to doxorubicin-based neoadjuvant chemotherapy in human breast cancer. Clin Cancer Res. 2005;11:8398–402.PubMedCrossRefGoogle Scholar
  26. 26.
    Ogston KN, Miller ID, Schofield AC, Spyrantis A, Pavlidou E, Sarkar TK, et al. Can patients’ likelihood of benefiting from primary chemotherapy for breast cancer be predicted before commencement of treatment? Breast Cancer Res Treat. 2004;86:181–9.PubMedCrossRefGoogle Scholar
  27. 27.
    Prisack HB, Karreman C, Modlich O, Audretsch W, Danae M, Rezai M, et al. Predictive biological markers for response of invasive breast cancer to anthracycline/cyclophosphamide-based primary (radio-) chemotherapy. Anticancer Res. 2005;25:4615–21.PubMedGoogle Scholar
  28. 28.
    von Minckwitz G, Sinn HP, Raab G, Loibl S, Blohmer JU, Eidtmann H, et al. Clinical response after two cycles compared to HER2, Ki-67, p53, and bcl-2 in independently predicting a pathological complete response after preoperative chemotherapy in patients with operable carcinoma of the breast. Breast Cancer Res. 2008;10:R30.CrossRefGoogle Scholar
  29. 29.
    Tewari M, Pradhan S, Singh U, Singh TB, Shukla HS. Assessment of predictive markers of response to neoadjuvant chemotherapy in breast cancer. Asian J Surg. 2010;33:157–67.PubMedCrossRefGoogle Scholar
  30. 30.
    Bozovic-Spasojevic I, Ameye L, Paesmans M, Larsimont D, Di Leo A, Dolci S, et al. Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: a retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapy. Breast. 2014. doi: 10.1016/j.breast.2014.03.012.PubMedGoogle Scholar
  31. 31.
    Hu S, Xu-Monette ZY, Tzankov A, Green T, Wu L, Balasubramanyam A, et al. MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from the International DLBCL Rituximab-Chop Consortium Program. Blood. 2013;121:4021–31. quiz 4250.PubMedCentralPubMedCrossRefGoogle Scholar
  32. 32.
    Campos L, Rouault JP, Sabido O, Oriol P, Roubi N, Vasselon C, et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood. 1993;81:3091–6.PubMedGoogle Scholar
  33. 33.
    Tothova E, Fricova M, Stecova N, Kafkova A, Elbertova A. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Neoplasma. 2002;49:141–4.PubMedGoogle Scholar
  34. 34.
    van Slooten HJ, van de Vijver MJ, van de Velde CJ, van Dierendonck JH. Loss of Bcl-2 in invasive breast cancer is associated with high rates of cell death, but also with increased proliferative activity. Br J Cancer. 1998;77:789–96.PubMedCentralPubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Jung Eun Choi
    • 1
  • Su Hwan Kang
    • 1
  • Soo Jung Lee
    • 1
  • Young Kyung Bae
    • 2
  1. 1.Department of SurgeryYeungnam University College of MedicineDaeguSouth Korea
  2. 2.Department of PathologyYeungnam University College of MedicineNam-guSouth Korea

Personalised recommendations